<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5173">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163851</url>
  </required_header>
  <id_info>
    <org_study_id>B1481003</org_study_id>
    <nct_id>NCT01163851</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin</brief_title>
  <official_title>A Phase 1 Study Evaluating The Pharmacokinetics And Pharmacodynamics Of Rn316 In Combination With Atorvastatin In Hypercholesterolemic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics
      of a single dose of PF-04950615 (RN316) in volunteers on stable doses of atorvastatin.
      PF-04950615 (RN316) is an investigational drug that is currently being studies as a
      cholesterol lowering therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615 (RN316)</measure>
    <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615 (RN316)</measure>
    <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-04950615 (RN316)</measure>
    <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of PF-04950615 (RN316)</measure>
    <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Clearance (CL) of PF-04950615 (RN316)</measure>
    <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of PF-04950615 (RN316)</measure>
    <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615 (RN316)</measure>
    <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Atorvastatin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Atorvastatin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Atorvastatin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Atorvastatin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Atorvastatin</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>LDL cholesterol is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Total Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Non-High-density Lipoprotein-Cholesterol (Non-HDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>HDL cholesterol is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>LDL cholesterol is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>HDL cholesterol is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</measure>
    <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver.. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of Additional Lipid Lowering Effects of PF-04950615 (RN316) in Combination With Atorvastatin on Days 4-64</measure>
    <time_frame>Day 4 to Day 64</time_frame>
    <safety_issue>No</safety_issue>
    <description>The median duration of the lipid-lowering effects (decrease in LDL-C levels by greater than or equal to 15 percent [%] compared to baseline) of PF-04950615 in combination with atorvastatin from Days 4 to 64 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Toxicity or Intolerable Dose Criteria</measure>
    <time_frame>Baseline, Days 1, 2, 3, 4, 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicity criteria included any of the following : serious adverse event (SAE), increased liver transaminases (alanine aminotransferase [ALT]/aspartate aminotransferase (AST) , increased bilirubin (in absence of ALT/AST elevations), pancreatitis, creatine kinase (CK) , hyper or hypoglycemia, decreased platelet count, increased serum creatinine, diarrhea, enteritis or nausea, prolongation of QTcF interval [Fridericia's Correction] and other considered appropriate by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Day 64</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 64 days after last dose that were absent before treatment or that worsened relative to pretreatment state. TEAEs (all causalities), treatment related TEAEs and common terminology criteria for adverse events (CTCAE) severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Physical Examination</measure>
    <time_frame>Baseline up to Day 64</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Complete physical examination was conducted to assess skin, ears, throat, cardiac, respiratory, gastrointestinal, and musculoskeletal systems for systemic TEAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Drug-Antibodies (ADA)</measure>
    <time_frame>Baseline up to Day 64</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants with positive antibody titer greater than 0 International Units/milliliter (IU/mL) was considered as antibody positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Vital Signs</measure>
    <time_frame>Baseline up to Day 64</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital sign parameters body temperature, blood pressure and heart rate were assessed to identify systemic TEAEs. TEAEs (all causalities), treatment related TEAEs and CTCAE severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Baseline up to Day 64</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ECG is used to measure the rate and regularity of heartbeats, as well as the size and position of the chambers, the presence of any damage to the heart, and the effects of drugs or devices used to regulate the heart. ECG parameters RR interval, PR interval, QRS complex, QT interval, [Bazett's Correction], QTcF interval [Fridericia's Correction] were assessed to identify systemic TEAEs. TEAEs (all causalities), treatment related TEAEs and CTCAE severity grades for AEs were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Laboratory Parameters</measure>
    <time_frame>Baseline up to Day 64</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Laboratory parameters alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, albumin, hemoglobin, protein, amylase, creatine kinase, lipase, basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets, white blood cells, bicarbonate, chloride, potassium, sodium, bilirubin, blood urea nitrogen, c-reactive protein , calcium, creatinine, direct bilirubin, glucose, magnesium, phosphate, uric acid, hematocrit, partial thromboplastin time , prothrombin time, red blood cells , urine pH, urine specific gravity were assessed to identify systemic TEAEs. TEAEs (all causalities), treatment related TEAEs and CTCAE severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>PF-04950615 (RN316)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4 mg/kg</intervention_name>
    <description>RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.</description>
    <arm_group_label>PF-04950615 (RN316)</arm_group_label>
    <other_name>PF-04950615 (RN316)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.5 mg/kg</intervention_name>
    <description>RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.</description>
    <arm_group_label>PF-04950615 (RN316)</arm_group_label>
    <other_name>PF-04950615 (RN316)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On stable doses of atorvastatin (40 mg daily) for 45 days prior to Day 1.

          -  BMI 18.5 to 40 kg/m2 inclusive, and body weight equal or lower than 150 kg.

        Exclusion Criteria:

          -  History of a cardiovascular event (e.g., MI ) during the past year.

          -  Poorly controlled Type 1 or Type 2 Diabetes mellitus (definition: uncontrolled
             diabetes is defined as HBIAc &gt;9%).

          -  Poorly controlled hypertension (uncontrolled hypertension is defined as a systolic
             blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90
             mm Hg, even with treatment). Subjects who have hypertension and are controlled on
             stable dosages of anti-hypertensive medications can be included.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premier Research Group, Limited</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dedicated Phase 1, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research Group Limited</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481003&amp;StudyName=Pharmacokinetic%20And%20Pharmacodynamic%20Study%20Of%20A%20Single-Dose%20Of%20PF-04950615%20%28RN316%29%20In%20Combination%20with%20Atorvastatin</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 20, 2015</lastchanged_date>
  <firstreceived_date>July 14, 2010</firstreceived_date>
  <firstreceived_results_date>April 20, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>LDL</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>High Cholesterol</keyword>
  <keyword>PF-04950615</keyword>
  <keyword>RN316</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
          <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
          <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
          <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
          <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Less than 18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>18 to 44 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>45 to 64 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Greater than or equal to 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615 (RN316)</title>
        <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).</description>
        <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615 (RN316)</title>
            <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).</description>
            <units>nanogram*hour/milliliter (ng*hr/mL)</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17950000" spread="2779600"/>
                  <measurement group_id="O2" value="933800" spread="376350"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615 (RN316)</title>
        <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615 (RN316)</title>
            <units>hrs</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.59" lower_limit="1.00" upper_limit="12.10"/>
                  <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="7.92"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of PF-04950615 (RN316)</title>
        <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Observed Plasma Concentration (Cmax) of PF-04950615 (RN316)</title>
            <units>ng/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105000" spread="16587"/>
                  <measurement group_id="O2" value="14030" spread="1680"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Decay Half-Life (t1/2) of PF-04950615 (RN316)</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Decay Half-Life (t1/2) of PF-04950615 (RN316)</title>
            <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
            <units>hrs</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="157.50" spread="33.22"/>
                  <measurement group_id="O2" value="61.00" spread="8.89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systemic Clearance (CL) of PF-04950615 (RN316)</title>
        <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
        <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Systemic Clearance (CL) of PF-04950615 (RN316)</title>
            <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
            <units>liter/hour (L/hr)</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.0185" spread="0.0041"/>
                  <measurement group_id="O2" value="0.0392" spread="0.0031"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution at Steady State (Vss) of PF-04950615 (RN316)</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.</description>
        <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Volume of Distribution at Steady State (Vss) of PF-04950615 (RN316)</title>
            <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.</description>
            <units>liter</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.248" spread="1.099"/>
                  <measurement group_id="O2" value="3.436" spread="0.583"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615 (RN316)</title>
        <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
        <time_frame>0 (pre-dose on Day 4), 1, 4, 8 and 12 hrs post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615 (RN316)</title>
            <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
            <units>ng*hr/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17960000" spread="2828500"/>
                  <measurement group_id="O2" value="1094000" spread="123640"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Atorvastatin</title>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Atorvastatin</title>
            <units>ng*hr/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="71.73" spread="32.22"/>
                  <measurement group_id="O2" value="89.17" spread="33.25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin</title>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin</title>
            <units>hrs</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.16" lower_limit="0.50" upper_limit="3.00"/>
                  <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="3.02"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Atorvastatin</title>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Observed Plasma Concentration (Cmax) of Atorvastatin</title>
            <units>ng/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15.79" spread="8.81"/>
                  <measurement group_id="O2" value="20.68" spread="10.58"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Decay Half-Life (t1/2) of Atorvastatin</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Decay Half-Life (t1/2) of Atorvastatin</title>
            <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
            <units>hrs</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.12" spread="1.38"/>
                  <measurement group_id="O2" value="5.09" spread="0.74"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance (CL/F) of Atorvastatin</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apparent Oral Clearance (CL/F) of Atorvastatin</title>
            <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
            <units>L/hr</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="557.50" spread="238.33"/>
                  <measurement group_id="O2" value="448.70" spread="196.91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vz/F) of Atorvastatin</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'N' (number of participants analyzed) is signifying those participants who were evaluable for this measure for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apparent Volume of Distribution (Vz/F) of Atorvastatin</title>
            <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
            <units>liter</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3950" spread="1952.8"/>
                  <measurement group_id="O2" value="3353" spread="1960.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>LDL cholesterol is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest. Here, 'n' is signifying those participants who were evaluable for particular category for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>LDL cholesterol is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>milligram/deciliter (mg/dL)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>LDL-C: Change at Day 5 (n = 12, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-14.30" spread="17.79"/>
                  <measurement group_id="O2" value="-16.2" spread="11.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Change at Day 6 (n = 11, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-28.50" spread="17.22"/>
                  <measurement group_id="O2" value="-34.00" spread="19.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Change at Day 7 (n = 11, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-33.30" spread="22.42"/>
                  <measurement group_id="O2" value="-47.20" spread="20.66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Change at Day 15 (n = 10, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-52.40" spread="35.31"/>
                  <measurement group_id="O2" value="-25.90" spread="31.94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Change at Day 22 (n = 9, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-57.20" spread="30.71"/>
                  <measurement group_id="O2" value="2.10" spread="36.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Change at Day 29 (n = 9, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-56.90" spread="35.21"/>
                  <measurement group_id="O2" value="9.40" spread="33.12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Change at Day 36 (n = 12, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-55.50" spread="23.64"/>
                  <measurement group_id="O2" value="3.40" spread="33.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Change at Day 43 (n = 12, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-32.30" spread="15.64"/>
                  <measurement group_id="O2" value="8.80" spread="34.18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Change at Day 50 (n = 12, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-11.40" spread="13.27"/>
                  <measurement group_id="O2" value="4.10" spread="29.02"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Change at Day 57 (n = 11, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.50" spread="22.25"/>
                  <measurement group_id="O2" value="10.90" spread="35.79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Change at Day 64 (n = 12, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.20" spread="24.62"/>
                  <measurement group_id="O2" value="12.10" spread="33.42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Total Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Total Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Total cholesterol: Change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-13.90" spread="19.48"/>
                  <measurement group_id="O2" value="-21.60" spread="15.04"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-33.30" spread="19.04"/>
                  <measurement group_id="O2" value="-38.30" spread="18.03"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-37.30" spread="25.72"/>
                  <measurement group_id="O2" value="-50.00" spread="20.50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-58.00" spread="39.02"/>
                  <measurement group_id="O2" value="-24.30" spread="38.29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-61.30" spread="34.91"/>
                  <measurement group_id="O2" value="7.50" spread="38.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-62.60" spread="32.81"/>
                  <measurement group_id="O2" value="8.40" spread="36.28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-56.30" spread="28.61"/>
                  <measurement group_id="O2" value="5.30" spread="36.43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-28.90" spread="19.61"/>
                  <measurement group_id="O2" value="9.80" spread="38.40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.30" spread="18.51"/>
                  <measurement group_id="O2" value="4.80" spread="34.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.30" spread="31.92"/>
                  <measurement group_id="O2" value="18.50" spread="34.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.10" spread="23.00"/>
                  <measurement group_id="O2" value="15.10" spread="31.48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Non-High-density Lipoprotein-Cholesterol (Non-HDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Non-High-density Lipoprotein-Cholesterol (Non-HDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Non-HDL-C: Change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.60" spread="21.90"/>
                  <measurement group_id="O2" value="-19.40" spread="15.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-31.20" spread="20.31"/>
                  <measurement group_id="O2" value="-35.90" spread="22.27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-36.40" spread="24.50"/>
                  <measurement group_id="O2" value="-47.60" spread="24.04"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-62.50" spread="39.40"/>
                  <measurement group_id="O2" value="-30.10" spread="36.18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-68.80" spread="32.78"/>
                  <measurement group_id="O2" value="4.70" spread="40.14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-69.00" spread="35.01"/>
                  <measurement group_id="O2" value="7.90" spread="39.76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-60.00" spread="29.56"/>
                  <measurement group_id="O2" value="3.50" spread="41.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-35.00" spread="18.14"/>
                  <measurement group_id="O2" value="6.60" spread="38.85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.00" spread="17.87"/>
                  <measurement group_id="O2" value="3.10" spread="37.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.50" spread="32.76"/>
                  <measurement group_id="O2" value="14.30" spread="39.36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.10" spread="20.13"/>
                  <measurement group_id="O2" value="12.70" spread="35.12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Triglycerides: Change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.20" spread="61.82"/>
                  <measurement group_id="O2" value="-15.80" spread="38.46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.70" spread="24.23"/>
                  <measurement group_id="O2" value="-9.90" spread="31.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.10" spread="38.09"/>
                  <measurement group_id="O2" value="-6.90" spread="44.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-19.60" spread="41.40"/>
                  <measurement group_id="O2" value="-21.10" spread="56.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.30" spread="45.63"/>
                  <measurement group_id="O2" value="13.60" spread="52.71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-17.40" spread="21.51"/>
                  <measurement group_id="O2" value="-8.20" spread="60.64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-22.20" spread="54.24"/>
                  <measurement group_id="O2" value="-0.30" spread="70.24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-13.10" spread="42.48"/>
                  <measurement group_id="O2" value="-10.90" spread="64.52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.60" spread="57.86"/>
                  <measurement group_id="O2" value="-4.90" spread="79.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.20" spread="63.42"/>
                  <measurement group_id="O2" value="16.50" spread="56.65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.60" spread="53.23"/>
                  <measurement group_id="O2" value="3.10" spread="31.78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>ApoB: Change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.90" spread="7.48"/>
                  <measurement group_id="O2" value="-13.10" spread="8.49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-22.10" spread="10.05"/>
                  <measurement group_id="O2" value="-24.90" spread="12.88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-28.30" spread="12.57"/>
                  <measurement group_id="O2" value="-29.50" spread="16.75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-41.90" spread="19.41"/>
                  <measurement group_id="O2" value="-21.70" spread="19.84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-44.00" spread="17.67"/>
                  <measurement group_id="O2" value="-3.30" spread="18.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-45.80" spread="17.61"/>
                  <measurement group_id="O2" value="-1.10" spread="23.99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-41.10" spread="15.09"/>
                  <measurement group_id="O2" value="-2.70" spread="19.76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-27.30" spread="7.48"/>
                  <measurement group_id="O2" value="-0.60" spread="18.47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.40" spread="10.53"/>
                  <measurement group_id="O2" value="-4.60" spread="20.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.10" spread="15.70"/>
                  <measurement group_id="O2" value="4.70" spread="15.51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.30" spread="10.70"/>
                  <measurement group_id="O2" value="5.80" spread="20.99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>ApoA1: Change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.00" spread="10.95"/>
                  <measurement group_id="O2" value="2.80" spread="8.70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.70" spread="10.79"/>
                  <measurement group_id="O2" value="-5.60" spread="8.07"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.40" spread="10.93"/>
                  <measurement group_id="O2" value="-1.50" spread="9.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.80" spread="8.30"/>
                  <measurement group_id="O2" value="12.10" spread="18.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.70" spread="11.13"/>
                  <measurement group_id="O2" value="16.10" spread="18.71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.50" spread="13.43"/>
                  <measurement group_id="O2" value="11.40" spread="27.34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.30" spread="10.87"/>
                  <measurement group_id="O2" value="11.50" spread="15.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.80" spread="10.73"/>
                  <measurement group_id="O2" value="14.90" spread="15.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.50" spread="8.64"/>
                  <measurement group_id="O2" value="5.20" spread="22.03"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.40" spread="11.77"/>
                  <measurement group_id="O2" value="24.50" spread="12.51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.50" spread="10.82"/>
                  <measurement group_id="O2" value="22.10" spread="19.44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>HDL cholesterol is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>HDL cholesterol is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>HDL: Change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.30" spread="5.60"/>
                  <measurement group_id="O2" value="-2.20" spread="7.95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.10" spread="4.16"/>
                  <measurement group_id="O2" value="-2.40" spread="11.71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.90" spread="4.41"/>
                  <measurement group_id="O2" value="-2.40" spread="12.63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.50" spread="8.01"/>
                  <measurement group_id="O2" value="5.90" spread="5.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.70" spread="4.65"/>
                  <measurement group_id="O2" value="2.80" spread="5.41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.50" spread="6.53"/>
                  <measurement group_id="O2" value="0.50" spread="5.99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.80" spread="5.52"/>
                  <measurement group_id="O2" value="1.90" spread="8.20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.10" spread="6.59"/>
                  <measurement group_id="O2" value="3.10" spread="5.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.80" spread="6.27"/>
                  <measurement group_id="O2" value="1.70" spread="7.71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.70" spread="5.26"/>
                  <measurement group_id="O2" value="4.20" spread="9.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.0" spread="6.02"/>
                  <measurement group_id="O2" value="2.40" spread="7.95"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>LDL cholesterol is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest. Here, 'n' is signifying those participants who were evaluable for particular category for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>LDL cholesterol is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>LDL-C: Percent change at Day 5 (n = 12, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-15.70" spread="23.36"/>
                  <measurement group_id="O2" value="-27.30" spread="23.60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Percent change at Day 6 (n = 11, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-33.80" spread="20.61"/>
                  <measurement group_id="O2" value="-47.00" spread="30.57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Percent change at Day 7 (n = 11, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-38.90" spread="24.15"/>
                  <measurement group_id="O2" value="-65.10" spread="31.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Percent change at Day 15 (n = 10, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-61.10" spread="31.98"/>
                  <measurement group_id="O2" value="-33.30" spread="29.80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Percent change at Day 22 (n = 9, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-71.60" spread="21.89"/>
                  <measurement group_id="O2" value="11.40" spread="46.23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Percent change at Day 29 (n = 9, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-68.70" spread="22.20"/>
                  <measurement group_id="O2" value="21.60" spread="46.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Percent change at Day 36 (n = 12, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-68.20" spread="15.59"/>
                  <measurement group_id="O2" value="14.90" spread="36.90"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Percent change at Day 43 (n = 12, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-41.80" spread="18.87"/>
                  <measurement group_id="O2" value="19.70" spread="38.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Percent change at Day 50 (n = 12, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-14.70" spread="17.10"/>
                  <measurement group_id="O2" value="13.70" spread="37.36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Percent change at Day 57 (n = 11, 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.40" spread="24.80"/>
                  <measurement group_id="O2" value="23.60" spread="47.93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL-C: Percent change at Day 64 (n = 12, 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.40" spread="31.22"/>
                  <measurement group_id="O2" value="25.60" spread="42.94"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Total Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.30" spread="11.81"/>
                  <measurement group_id="O2" value="-14.60" spread="8.87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-21.20" spread="10.16"/>
                  <measurement group_id="O2" value="-26.20" spread="10.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-23.10" spread="14.16"/>
                  <measurement group_id="O2" value="-34.10" spread="11.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-35.40" spread="19.65"/>
                  <measurement group_id="O2" value="-14.40" spread="18.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-38.40" spread="16.70"/>
                  <measurement group_id="O2" value="7.40" spread="21.95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-39.40" spread="14.50"/>
                  <measurement group_id="O2" value="7.40" spread="19.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-36.30" spread="14.00"/>
                  <measurement group_id="O2" value="7.00" spread="21.50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-18.90" spread="10.34"/>
                  <measurement group_id="O2" value="9.00" spread="21.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.70" spread="11.17"/>
                  <measurement group_id="O2" value="6.00" spread="19.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.50" spread="19.31"/>
                  <measurement group_id="O2" value="14.30" spread="20.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total cholesterol: Percent change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.10" spread="14.86"/>
                  <measurement group_id="O2" value="12.50" spread="18.07"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.90" spread="20.47"/>
                  <measurement group_id="O2" value="-20.30" spread="15.38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-28.70" spread="16.69"/>
                  <measurement group_id="O2" value="-37.60" spread="26.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-32.80" spread="18.81"/>
                  <measurement group_id="O2" value="-50.00" spread="26.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-56.00" spread="26.05"/>
                  <measurement group_id="O2" value="-25.40" spread="26.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-63.90" spread="18.00"/>
                  <measurement group_id="O2" value="14.70" spread="40.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-63.90" spread="17.86"/>
                  <measurement group_id="O2" value="16.10" spread="40.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-57.30" spread="16.60"/>
                  <measurement group_id="O2" value="14.00" spread="36.59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-35.70" spread="16.64"/>
                  <measurement group_id="O2" value="14.30" spread="35.80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.40" spread="16.55"/>
                  <measurement group_id="O2" value="12.90" spread="38.29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.80" spread="26.93"/>
                  <measurement group_id="O2" value="23.80" spread="44.36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-HDL-C: Percent change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.60" spread="20.30"/>
                  <measurement group_id="O2" value="21.20" spread="35.27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Triglycerides: Percent change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.20" spread="65.46"/>
                  <measurement group_id="O2" value="-3.30" spread="24.88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Percent change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.40" spread="20.29"/>
                  <measurement group_id="O2" value="1.10" spread="22.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Percent change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.00" spread="21.20"/>
                  <measurement group_id="O2" value="0.50" spread="27.67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Percent change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.10" spread="41.62"/>
                  <measurement group_id="O2" value="-1.40" spread="35.76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Percent change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.20" spread="30.73"/>
                  <measurement group_id="O2" value="19.90" spread="42.17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Percent change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-14.60" spread="20.02"/>
                  <measurement group_id="O2" value="0.80" spread="34.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Percent change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-15.90" spread="32.23"/>
                  <measurement group_id="O2" value="12.20" spread="45.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Percent change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-7.90" spread="25.94"/>
                  <measurement group_id="O2" value="3.20" spread="33.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Percent change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.60" spread="42.61"/>
                  <measurement group_id="O2" value="12.10" spread="49.12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Percent change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.10" spread="45.52"/>
                  <measurement group_id="O2" value="22.20" spread="41.65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides: Percent change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28.60" spread="42.51"/>
                  <measurement group_id="O2" value="7.60" spread="30.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>ApoB: Percent change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-13.50" spread="9.25"/>
                  <measurement group_id="O2" value="-17.10" spread="11.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Percent change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-26.90" spread="11.01"/>
                  <measurement group_id="O2" value="-31.10" spread="13.84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Percent change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-33.80" spread="12.27"/>
                  <measurement group_id="O2" value="-36.10" spread="15.68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Percent change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-48.60" spread="13.82"/>
                  <measurement group_id="O2" value="-24.80" spread="18.18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Percent change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-51.50" spread="11.04"/>
                  <measurement group_id="O2" value="-0.70" spread="19.21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Percent change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-53.70" spread="10.37"/>
                  <measurement group_id="O2" value="3.80" spread="26.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Percent change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-48.80" spread="9.97"/>
                  <measurement group_id="O2" value="1.50" spread="22.64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Percent change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-33.80" spread="8.98"/>
                  <measurement group_id="O2" value="2.70" spread="18.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Percent change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-13.70" spread="13.70"/>
                  <measurement group_id="O2" value="-1.50" spread="21.38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Percent change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.80" spread="18.03"/>
                  <measurement group_id="O2" value="9.40" spread="19.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoB: Percent change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.00" spread="12.82"/>
                  <measurement group_id="O2" value="11.50" spread="25.50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>HDL cholesterol is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>HDL cholesterol is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>HDL: Percent change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.50" spread="11.27"/>
                  <measurement group_id="O2" value="-1.70" spread="10.93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Percent change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.60" spread="8.24"/>
                  <measurement group_id="O2" value="-0.90" spread="18.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Percent change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.10" spread="9.29"/>
                  <measurement group_id="O2" value="-0.90" spread="18.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Percent change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.10" spread="19.48"/>
                  <measurement group_id="O2" value="13.40" spread="12.40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Percent change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.90" spread="9.65"/>
                  <measurement group_id="O2" value="8.00" spread="11.23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Percent change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.00" spread="15.04"/>
                  <measurement group_id="O2" value="3.00" spread="11.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Percent change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.80" spread="11.50"/>
                  <measurement group_id="O2" value="7.50" spread="17.15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Percent change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.50" spread="15.67"/>
                  <measurement group_id="O2" value="8.70" spread="8.79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Percent change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.10" spread="13.89"/>
                  <measurement group_id="O2" value="6.70" spread="14.20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Percent change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.10" spread="11.93"/>
                  <measurement group_id="O2" value="14.00" spread="19.37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL: Percent change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.50" spread="12.37"/>
                  <measurement group_id="O2" value="8.20" spread="12.15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
        <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver.. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
        <time_frame>Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64</title>
            <description>ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver.. Fasting was required at least 10 hours before blood sample collection. Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>ApoA1: Percent change at Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.90" spread="7.48"/>
                  <measurement group_id="O2" value="2.10" spread="6.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Percent change at Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.00" spread="7.27"/>
                  <measurement group_id="O2" value="-4.20" spread="6.80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Percent change at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.90" spread="7.14"/>
                  <measurement group_id="O2" value="-0.80" spread="7.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Percent change at Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.10" spread="6.31"/>
                  <measurement group_id="O2" value="9.10" spread="12.52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Percent change at Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.40" spread="8.27"/>
                  <measurement group_id="O2" value="11.50" spread="11.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Percent change at Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.20" spread="9.94"/>
                  <measurement group_id="O2" value="7.80" spread="17.55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Percent change at Day 36</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.30" spread="7.64"/>
                  <measurement group_id="O2" value="8.80" spread="11.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Percent change at Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.80" spread="7.73"/>
                  <measurement group_id="O2" value="11.60" spread="12.44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Percent change at Day 50</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.50" spread="5.77"/>
                  <measurement group_id="O2" value="3.50" spread="16.45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Percent change at Day 57</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.40" spread="8.71"/>
                  <measurement group_id="O2" value="18.80" spread="7.84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ApoA1: Percent change at Day 64</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.80" spread="7.48"/>
                  <measurement group_id="O2" value="16.90" spread="14.18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Durability of Additional Lipid Lowering Effects of PF-04950615 (RN316) in Combination With Atorvastatin on Days 4-64</title>
        <description>The median duration of the lipid-lowering effects (decrease in LDL-C levels by greater than or equal to 15 percent [%] compared to baseline) of PF-04950615 in combination with atorvastatin from Days 4 to 64 was reported.</description>
        <time_frame>Day 4 to Day 64</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Durability of Additional Lipid Lowering Effects of PF-04950615 (RN316) in Combination With Atorvastatin on Days 4-64</title>
            <description>The median duration of the lipid-lowering effects (decrease in LDL-C levels by greater than or equal to 15 percent [%] compared to baseline) of PF-04950615 in combination with atorvastatin from Days 4 to 64 was reported.</description>
            <units>days</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48.5" spread="16.36" lower_limit="2.0" upper_limit="64.0"/>
                  <measurement group_id="O2" value="18.0" spread="15.68" lower_limit="0.0" upper_limit="59.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Toxicity or Intolerable Dose Criteria</title>
        <description>Toxicity criteria included any of the following : serious adverse event (SAE), increased liver transaminases (alanine aminotransferase [ALT]/aspartate aminotransferase (AST) , increased bilirubin (in absence of ALT/AST elevations), pancreatitis, creatine kinase (CK) , hyper or hypoglycemia, decreased platelet count, increased serum creatinine, diarrhea, enteritis or nausea, prolongation of QTcF interval [Fridericia's Correction] and other considered appropriate by investigator.</description>
        <time_frame>Baseline, Days 1, 2, 3, 4, 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety Analysis Set (SAS) population included all participants who met the study enrollment criteria and had received any amount of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Toxicity or Intolerable Dose Criteria</title>
            <description>Toxicity criteria included any of the following : serious adverse event (SAE), increased liver transaminases (alanine aminotransferase [ALT]/aspartate aminotransferase (AST) , increased bilirubin (in absence of ALT/AST elevations), pancreatitis, creatine kinase (CK) , hyper or hypoglycemia, decreased platelet count, increased serum creatinine, diarrhea, enteritis or nausea, prolongation of QTcF interval [Fridericia's Correction] and other considered appropriate by investigator.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 64 days after last dose that were absent before treatment or that worsened relative to pretreatment state. TEAEs (all causalities), treatment related TEAEs and common terminology criteria for adverse events (CTCAE) severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade.</description>
        <time_frame>Baseline up to Day 64</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>SAS population included all participants who met the study enrollment criteria and had received any amount of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)</title>
            <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 64 days after last dose that were absent before treatment or that worsened relative to pretreatment state. TEAEs (all causalities), treatment related TEAEs and common terminology criteria for adverse events (CTCAE) severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>TEAEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SAEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 AEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 2 AEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 AEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TEAEs (Treatment related)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SAEs (Treatment related)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 AEs (Treatment related)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 AEs (Treatment related)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Physical Examination</title>
        <description>Complete physical examination was conducted to assess skin, ears, throat, cardiac, respiratory, gastrointestinal, and musculoskeletal systems for systemic TEAEs.</description>
        <time_frame>Baseline up to Day 64</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>SAS population included all participants who met the study enrollment criteria and had received any amount of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Physical Examination</title>
            <description>Complete physical examination was conducted to assess skin, ears, throat, cardiac, respiratory, gastrointestinal, and musculoskeletal systems for systemic TEAEs.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-Drug-Antibodies (ADA)</title>
        <description>Participants with positive antibody titer greater than 0 International Units/milliliter (IU/mL) was considered as antibody positive.</description>
        <time_frame>Baseline up to Day 64</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>SAS population included all participants who met the study enrollment criteria and had received any amount of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Anti-Drug-Antibodies (ADA)</title>
            <description>Participants with positive antibody titer greater than 0 International Units/milliliter (IU/mL) was considered as antibody positive.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Vital Signs</title>
        <description>Vital sign parameters body temperature, blood pressure and heart rate were assessed to identify systemic TEAEs. TEAEs (all causalities), treatment related TEAEs and CTCAE severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade.</description>
        <time_frame>Baseline up to Day 64</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>SAS population included all participants who met the study enrollment criteria and had received any amount of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Vital Signs</title>
            <description>Vital sign parameters body temperature, blood pressure and heart rate were assessed to identify systemic TEAEs. TEAEs (all causalities), treatment related TEAEs and CTCAE severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>TEAEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TEAEs (Treatment related)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 AEs: (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 2 AEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Electrocardiogram (ECG) Parameters</title>
        <description>ECG is used to measure the rate and regularity of heartbeats, as well as the size and position of the chambers, the presence of any damage to the heart, and the effects of drugs or devices used to regulate the heart. ECG parameters RR interval, PR interval, QRS complex, QT interval, [Bazett's Correction], QTcF interval [Fridericia's Correction] were assessed to identify systemic TEAEs. TEAEs (all causalities), treatment related TEAEs and CTCAE severity grades for AEs were reported.</description>
        <time_frame>Baseline up to Day 64</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>SAS population included all participants who met the study enrollment criteria and had received any amount of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Electrocardiogram (ECG) Parameters</title>
            <description>ECG is used to measure the rate and regularity of heartbeats, as well as the size and position of the chambers, the presence of any damage to the heart, and the effects of drugs or devices used to regulate the heart. ECG parameters RR interval, PR interval, QRS complex, QT interval, [Bazett's Correction], QTcF interval [Fridericia's Correction] were assessed to identify systemic TEAEs. TEAEs (all causalities), treatment related TEAEs and CTCAE severity grades for AEs were reported.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>TEAEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TEAEs (Treatment related)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 AEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Laboratory Parameters</title>
        <description>Laboratory parameters alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, albumin, hemoglobin, protein, amylase, creatine kinase, lipase, basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets, white blood cells, bicarbonate, chloride, potassium, sodium, bilirubin, blood urea nitrogen, c-reactive protein , calcium, creatinine, direct bilirubin, glucose, magnesium, phosphate, uric acid, hematocrit, partial thromboplastin time , prothrombin time, red blood cells , urine pH, urine specific gravity were assessed to identify systemic TEAEs. TEAEs (all causalities), treatment related TEAEs and CTCAE severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade.</description>
        <time_frame>Baseline up to Day 64</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>SAS population included all participants who met the study enrollment criteria and had received any amount of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
            <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
            <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Systemic Treatment Emergent Adverse Events (TEAEs) Identified by Laboratory Parameters</title>
            <description>Laboratory parameters alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, albumin, hemoglobin, protein, amylase, creatine kinase, lipase, basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets, white blood cells, bicarbonate, chloride, potassium, sodium, bilirubin, blood urea nitrogen, c-reactive protein , calcium, creatinine, direct bilirubin, glucose, magnesium, phosphate, uric acid, hematocrit, partial thromboplastin time , prothrombin time, red blood cells , urine pH, urine specific gravity were assessed to identify systemic TEAEs. TEAEs (all causalities), treatment related TEAEs and CTCAE severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>TEAEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TEAEs (Treatment related)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 AEs (All causalities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 AEs (Treatment related)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 2 AEs (Treatemnt related)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 AEs (Treatment related)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin + PF-04950615 (RN316) 4 mg/kg</title>
          <description>Atorvastatin tablet 40 milligram (mg) orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 4 milligram/kilogram (mg/kg) over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin + PF-04950615 (RN316) 0.5 mg/kg</title>
          <description>Atorvastatin tablet 40 mg orally once daily from Day 1 to Day 7 administered by sponsor, along with PF-04950615 (RN316) 0.5 mg/kg over 60 minutes intravenous infusion on Day 4 during treatment phase. Participants were on self administered chronic stable background atorvastatin therapy, 40 mg once daily prior to, and after treatment phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All determinations of primary or secondary outcomes were arbitrary as study did not specify primary or secondary outcome measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
